Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025
Cerevance (CRVN) has announced two upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto from July 27-31, 2025. The first presentation will discuss Phase 1 clinical trial results of CVN293, a KCNK13 inhibitor targeting neuroinflammation, which demonstrated good CNS exposure and tolerability. The second presentation will showcase findings from their proprietary NETSseq platform regarding astrocyte function in Alzheimer's disease.
The presentations are scheduled for July 28 and July 30, 2025, respectively, and will contribute to the company's ongoing research in neurodegenerative diseases.
Cerevance (CRVN) ha annunciato due prossime presentazioni alla Conferenza Internazionale dell'Associazione Alzheimer (AAIC) 2025 che si terr脿 a Toronto dal 27 al 31 luglio 2025. La prima presentazione riguarder脿 i risultati della fase 1 dello studio clinico su CVN293, un inibitore di KCNK13 che mira alla neuroinfiammazione, dimostrando una buona esposizione nel sistema nervoso centrale e tollerabilit脿. La seconda presentazione illustrer脿 i risultati ottenuti dalla loro piattaforma proprietaria NETSseq relativi alla funzione degli astrociti nella malattia di Alzheimer.
Le presentazioni sono programmate rispettivamente per il 28 e il 30 luglio 2025 e contribuiranno alla ricerca continua dell'azienda sulle malattie neurodegenerative.
Cerevance (CRVN) ha anunciado dos pr贸ximas presentaciones en la Conferencia Internacional de la Asociaci贸n de Alzheimer (AAIC) 2025 en Toronto, del 27 al 31 de julio de 2025. La primera presentaci贸n tratar谩 los resultados del ensayo cl铆nico de fase 1 de CVN293, un inhibidor de KCNK13 dirigido a la neuroinflamaci贸n, que mostr贸 buena exposici贸n en el sistema nervioso central y tolerabilidad. La segunda presentaci贸n mostrar谩 hallazgos de su plataforma propietaria NETSseq sobre la funci贸n de los astrocitos en la enfermedad de Alzheimer.
Las presentaciones est谩n programadas para el 28 y 30 de julio de 2025, respectivamente, y contribuir谩n a la investigaci贸n continua de la compa帽铆a en enfermedades neurodegenerativas.
Cerevance (CRVN)電� 2025雲� 7鞗� 27鞚茧秬韯� 31鞚缄箤歆� 韱犽韱犾棎靹� 鞐措Μ電� 甑牅 鞎岇笭頃橃澊毹� 順戫殞 頃欖垹雽�須�(AAIC) 2025鞐愳劀 霊� 彀 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 觳� 氩堨Ц 氚滍憸電� 鞁犼步鞐检鞚� 響滌爜鞙茧 頃橂姅 KCNK13 鞏奠牅鞝滌澑 CVN293鞚� 1靸� 鞛勳儊鞁滍棙 瓴瓣臣毳� 雼る（氅�, 欷戩稊鞁犼步瓿�(CNS) 雮� 鞖办垬頃� 雲胳稖瓿� 雮挫暯靹膘潉 鞛呾頄堨姷雼堧嫟. 霊� 氩堨Ц 氚滍憸電� 鞎岇笭頃橃澊毹鸽硲鞐愳劀 靹膘儊甑愳劯韽� 旮半姤鞐� 甏�頃� 鞛愳泊 臧滊皽 NETSseq 頂岆灚韽�鞚� 鞐瓣惮 瓴瓣臣毳� 靻岅皽頃� 鞓堨爼鞛呺媹雼�.
氚滍憸電� 臧侁皝 2025雲� 7鞗� 28鞚缄臣 30鞚检棎 鞓堨爼霅橃柎 鞛堨溂氅�, 須岇偓鞚� 鞁犼步韲错枆靹� 歆堩櫂 鞐瓣惮鞐� 旮办棳頃� 瓴冹瀰雼堧嫟.
Cerevance (CRVN) a annonc茅 deux pr茅sentations 脿 venir lors de la Conf茅rence Internationale de l'Association Alzheimer (AAIC) 2025 脿 Toronto, du 27 au 31 juillet 2025. La premi猫re pr茅sentation portera sur les r茅sultats de l'essai clinique de phase 1 de CVN293, un inhibiteur de KCNK13 ciblant la neuroinflammation, ayant d茅montr茅 une bonne exposition au syst猫me nerveux central et une bonne tol茅rance. La seconde pr茅sentera les d茅couvertes issues de leur plateforme propri茅taire NETSseq concernant la fonction des astrocytes dans la maladie d'Alzheimer.
Les pr茅sentations sont pr茅vues respectivement les 28 et 30 juillet 2025 et contribueront aux recherches en cours de l'entreprise sur les maladies neurod茅g茅n茅ratives.
Cerevance (CRVN) hat zwei bevorstehende Pr盲sentationen auf der Alzheimer's Association International Conference (AAIC) 2025 angek眉ndigt, die vom 27. bis 31. Juli 2025 in Toronto stattfindet. Die erste Pr盲sentation wird die Ergebnisse der Phase-1-Studie von CVN293 vorstellen, einem KCNK13-Inhibitor, der auf Neuroinflammation abzielt und eine gute ZNS-Bioverf眉gbarkeit sowie Vertr盲glichkeit zeigte. Die zweite Pr盲sentation wird Erkenntnisse ihrer propriet盲ren NETSseq-Plattform zur Funktion von Astrozyten bei Alzheimer pr盲sentieren.
Die Pr盲sentationen sind f眉r den 28. und 30. Juli 2025 geplant und werden zur laufenden Forschung des Unternehmens im Bereich neurodegenerativer Erkrankungen beitragen.
- None.
- None.
- Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-tolerated
- Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer鈥檚 disease
鈥岯OSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025 being held in Toronto from July 27-31, 2025.
Details of the poster presentations at AAIC 2025 are as follows:
Title:聽CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics (#106386)
- Session Date/Time:聽Monday, July 28, 2025, 7:30 a.m. 鈥� 4:15 p.m. ET
Title:聽NETSseq unveils deep molecular insights into astrocyte function in Alzheimer鈥檚 disease in the human brain (#106433)
- Session Date/Time:聽Wednesday, July 30, 2025, 7:30 a.m. 鈥� 4:15 p.m. ET
About NETSseq
Our proprietary platform, Nuclear Enriched Transcript Sort sequencing (NETSseq), enables the identification of subtle molecular changes that drive disease progression. By analyzing brain tissue from a diverse pool of over 20,000 donors, ranging in age from 8 to 104, and including both healthy individuals and those with various central nervous system (CNS) disorders, NETSseq allows us to identify targets that are expressed at very low levels, are present in rare cell types, or change over time as a disease progresses. This transformative tool provides deep insights into the molecular drivers of disease within specific cell populations, expanding our understanding and treatment of neurodegenerative diseases. It enables us to pursue therapies that directly address underlying disease mechanisms. Our platform has been instrumental in the development of our investigational assets, forming a cornerstone of our innovative approach to CNS drug discovery.
About CVN293
CVN293 is an investigational, highly selective oral inhibitor of the potassium two pore domain channel subfamily K member 13 (KCNK13). By selectively inhibiting KCNK13, a potentially novel regulator of NLRP3 inflammasome activation, CVN293 aims to reduce neuroinflammation and slow disease progression in a variety of neurodegenerative disorders. This mechanism may provide a disease-modifying approach for challenging CNS disorders. Additionally, modulation of KCNK13 may have therapeutic benefit in obesity. KCNK13 was identified by Cerevance鈥檚 proprietary NETSseq platform.
About Cerevance
Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative and central nervous system-controlled metabolic disorders. Our most advanced investigational treatment, solengepras, is currently in Phase 3 development and has the potential to be a first-in-class, oral non-dopaminergic therapy for both the motor and non-motor symptoms of Parkinson's disease. Our second investigational therapy, CVN766, is designed to be a highly selective oral antagonist of the orexin 1 receptor for the potential treatment of binge eating disorder and schizophrenia. Our third investigational treatment, CVN293, is a highly selective investigational oral inhibitor targeting KCNK13. CVN293 represents a potentially novel intervention point for neurodegenerative disorders and obesity.
For more information, please visit聽聽and follow us on聽听补苍诲听.
颁辞苍迟补肠迟蝉听
颁别谤别惫补苍肠别:听
Johnna Sim玫es, [email protected]
Media:
April Dovorany, [email protected], +1-262-909-8739
FAQ
When and where is Cerevance (CRVN) presenting at AAIC 2025?
What are the key findings from Cerevance's Phase 1 trial of CVN293?
What is the focus of Cerevance's NETSseq platform presentation at AAIC 2025?
What therapeutic areas does Cerevance focus on?
